|
|
| (123 intermediate revisions by 6 users not shown) |
| Line 1: |
Line 1: |
| == Initial antimicrobial therapy for acutely ill ==
| | {{Antibiotics by diagnosis navigation}} |
| | |
| '''Hospitalized adults pending identification of causative organism'''
| |
| | |
| {| cellspacing="0" cellpadding="2" border="1" class="pbSortable" | |
| |-
| |
| | '''Suspected Clinical Diagnosis'''
| |
| | '''Likely Etiologic Diagnosis'''
| |
| | '''Drugs of Choice'''
| |
| |-
| |
| | Meningitis, bacterial, community-acquired<sup>6</sup>
| |
| | Pneumococcus<sup>1</sup>, meningococcus
| |
| | Cefotaxime<sup>2</sup>, 2–3 g IV every 6 hours; '''or''' ceftriaxone, 2 g IV every 12 hours plus vancomycin, 10 mg/kg IV every 8 hours
| |
| |-
| |
| | Meningitis, bacterial, age > 50, community-acquired<sup>6</sup>
| |
| | Pneumococcus, meningococcus, ''Listeria monocytogenes''<sup>3</sup>, gram-negative bacilli
| |
| | Ampicillin, 2 g IV every 4 hours, plus Cefotaxime or ceftriaxone and vancomycin
| |
| |-
| |
| | Meningitis, postoperative (or posttraumatic)<sup>6</sup>
| |
| | ''S aureus,'' gram-negative bacilli (pneumococcus, in posttraumatic)<br>
| |
| | Vancomycin, 10 mg/kg IV every 8 hours, plus ceftazidime, 3 g IV every 8 hours
| |
| |-
| |
| | Brain abscess
| |
| | Mixed anaerobes, pneumococci, streptococci
| |
| | Penicillin G, 4 million units IV every 4 hours, plus metronidazole, 500 mg orally every 8 hours; '''or''' Cefotaxime or ceftriaxone plus metronidazole, 500 mg orally every 8 hours
| |
| |-
| |
| | Pneumonia, acute, community-acquired, severe
| |
| | Pneumococci, ''M pneumoniae, ''''Legionella'''', C pneumoniae''<br>
| |
| | Doxycycline, 100 mg IV or orally every 12 hours (or azithromycin), plus Cefotaxime, 2 g IV every 8 hours (or ceftriaxone, 1 g IV every 24 hours); '''or''' a fluoroquinolone<sup>5</sup> alone
| |
| |-
| |
| | Pneumonia, postoperative or nosocomial
| |
| | ''S aureus,'' mixed anaerobes, gram-negative bacilli<br>
| |
| | Cefapime, 2 g IV every 8 hours; '''or ''' , 2 g IV every 8 hours; '''or''' piperacillin-tazobactam, 45 g IV every 6 hours; '''or''' imipenem, 500 mg IV every 6 hours; '''or''' meropenem, 1 g IV every 8 hours plus tobramycin, 5 mg/kg IV every 24 hours; '''or ''' ciprofloxacin, 400 mg IV every 12 hours; '''or ''' levofloxacin, 500 mg IV every 24 hours plus vancomycin, 15 mg/kg IV every 12 hours
| |
| |-
| |
| | Endocarditis, acute (including injection drug user)
| |
| | ''S aureus, E faecalis,'' gram-negative aerobic bacteria, viridans streptococci<br>
| |
| | vancomycin, 15 mg/kg IV every 12 hours, plus gentamicin, 1 mg/kg every 8 hours
| |
| |-
| |
| | Septic thrombophlebitis (eg, IV tubing, IV shunts)
| |
| | ''S aureus,'' gram-negative aerobic bacteria<br>
| |
| | Vancomycin, 15 mg/kg IV every 12 hours plus ciprofloxacin, 400 mg IV every 12 hours; '''or''' levofloxacin, 500 mg IV every 24 hours; '''or''' ceftriaxone, 1 g IV every 24 hours
| |
| |-
| |
| | Osteomyelitis
| |
| | ''S aureus''
| |
| | Nafcillin, 2 g IV every 4 hours; '''or''' cefazolin, 2 g IV every 8 hours
| |
| |-
| |
| | Septic arthritis
| |
| | ''S aureus, N gonorrhoeae''
| |
| | Ceftriaxone , 1–2 g IV every 24 hours
| |
| |-
| |
| | Pyelonephritis with flank pain and fever (recurrent urinary tract infection)
| |
| | ''E coli, Klebsiella, Enterobacter, Pseudomonas''<br>
| |
| | Ceftriaxone, 1g IV every 24 hours; '''or''' ciprofloxacin, 400 mg IV every 12 hours (500 mg orally); '''or''' levofloxacin, 500 mg once daily (IV/PO)
| |
| |-
| |
| | Fever in neutropenic patient receiving cancer chemotherapy
| |
| | ''S aureus, Pseudomonas, Klebsiella, E coli''<br>
| |
| | Ceftazidime, 2 g IV every 8 hours; '''or''' cefepime, 2 g IV every 8 hours
| |
| |-
| |
| | Intra-abdominal sepsis (eg, postoperative, peritonitis, cholecystitis)
| |
| | Gram-negative bacteria, ''Bacteroides,'' anaerobic bacteria, streptococci, clostridia
| |
| | Piperacillin-tazobactam or ticarcillin-clavulanate, 3.1 g IV every 6 hours; '''or''' ertapenem, 1 g every 24 hours; '''or''' moxifloxacin, 400 mg IV every 24 hours
| |
| |}
| |
| | |
| <sup>1</sup>Some strains may be resistant to penicillin. Vancomycin can be used with or without rifampin.
| |
| | |
| <sup>2</sup>Cefotaxime, ceftriaxone, ceftazidime, or ceftizoxime can be used. Most studies on meningitis have been with cefotaxime or ceftriaxone (see text).
| |
| | |
| <sup>3</sup>TMP-SMZ can be used to treat ''Listeria monocytogenes'' in patients allergic to penicillin in a dosage of 15–20 mg/kg of TMP in three or four divided doses.
| |
| | |
| <sup>4</sup>Depending on local drug susceptibility pattern, use tobramycin, 5 mg/kg/d, or amikacin, 15 mg/kg/d, in place of gentamicin.
| |
| | |
| <sup>5</sup>Gatifloxacin, levofloxacin, moxifloxacin
| |
| | |
| <sup>6</sup>Remember to give steroids concomitatntly or 15 minutes prior to antibiotics for acute bacterial meningitis
| |
| | |
| | |
| | |
| == Antibiotics By Diagnosis<br> ==
| |
| | |
| {| cellspacing="0" cellpadding="2" border="1" align="left" style="width: 483px; height: 2459px;"
| |
| |-
| |
| | '''Diagnosis'''<br>
| |
| | '''Commonly Used Antibiotic(s)'''<br>
| |
| |-
| |
| | [[Meningitis]]<br>
| |
| |
| |
| Vancomycin 750mg (15mg/kg) IV
| |
| | |
| ''PLUS''
| |
| | |
| Ceftriaxone 2g (50mg/kg) IV
| |
| | |
| ''ADD''
| |
| | |
| Ampicillin 2g (50mg/kg) IV ''if concern for Listeria''
| |
| | |
| |-
| |
| | [[Otitis Media (Peds)|Otitis Media]]<br>
| |
| |
| |
| Amoxicillin 500mg (45mg/kg) PO Q12
| |
| | |
| ''OR''
| |
| | |
| Augmentin 500mg (45mg/kg) PO Q12
| |
| | |
| ''OR''
| |
| | |
| Cefdinir 600mg (14mg/kg) PO Daily
| |
| | |
| |-
| |
| | [[Otitis Externa]]<br>
| |
| |
| |
| Ciprodex 3gtt Q12
| |
| | |
| ''OR''
| |
| | |
| Polysporin otic 5gtt Q6
| |
| | |
| |-
| |
| | Pharyngitis<br>
| |
| |
| |
| Bicillin 1.2 million units (25k/kg) IM
| |
| | |
| ''OR''
| |
| | |
| Azithromycin 500mg (12mg/kg) PO Daily
| |
| | |
| |-
| |
| | [[Corneal Abrasion]]<br>
| |
| |
| |
| Erythromycin ophthalmic Q6
| |
| | |
| ''OR''
| |
| | |
| Levofloxacin 0.5% 2gtt Q2 ''if patient is a contact user''
| |
| | |
| |-
| |
| | [[Orbital Cellulitis]]<br>
| |
| | Vancomycin 1g (15mg/kg) IV Q12<br>
| |
| |-
| |
| | [[Appendicitis]]
| |
| |
| |
| Zosyn 4.5g (100 mg/kg) IV Q6
| |
| | |
| ''OR''
| |
| | |
| Flagyl 500mg (7.5mg/kg) IV Q6
| |
| | |
| ''PLUS''
| |
| | |
| Ciprofloxacin 400mg IV Q12
| |
| | |
| |-
| |
| | [[Cholecystitis]]<br>
| |
| |
| |
| Augmentin 3g IV Q6
| |
| | |
| ''OR''
| |
| | |
| Imipenem/Cilastin 500mg IV Q6
| |
| | |
| |-
| |
| | [[Diverticulitis]]
| |
| |
| |
| Flagyl 500mg PO Q6
| |
| | |
| ''PLUS''
| |
| | |
| Ciprofloxacin 750mg PO Q12
| |
| | |
| |-
| |
| | Infectious [[Diarrhea]]
| |
| |
| |
| Empiric: Cipro 500mg PO Q12 x3d
| |
| | |
| Giardia: Flagyl 500mg PO Q8 x5d
| |
| | |
| C. diff: Flagyl 500mg PO Q8 x14d
| |
| | |
| |-
| |
| | [[Epididymitis]]
| |
| |
| |
| Age <35 (gonorrhea suspected):
| |
| | |
| Doxycycline 100mg PO Q12 x14d
| |
| | |
| ''PLUS''
| |
| | |
| Cefixime 400mg PO once
| |
| | |
| Age >35 (gonorrhea not suspected):
| |
| | |
| Ciprofloxacin 500mg PO Q12 x14d
| |
| | |
| |-
| |
| | Cervicitis/Urethritis
| |
| |
| |
| Cefixime 400mg PO once
| |
| | |
| ''OR''
| |
| | |
| Azithromycin 1g PO once
| |
| | |
| ''ADD''
| |
| | |
| Flagyl 2g PO once ''if concern for trichomoniasis''
| |
| | |
| |-
| |
| | [[PID]]<br>
| |
| |
| |
| Ceftriaxone 250mg 1M once
| |
| | |
| ''PLUS''
| |
| | |
| Doxycycline 100 mg PO Q12 x14d
| |
| | |
| |-
| |
| | [[UTI]]<br>
| |
| |
| |
| Macrobid 100mg PO BID x7d
| |
| | |
| ''OR''
| |
| | |
| Bactrim DS PO Q12 x3d
| |
| | |
| ''OR''
| |
| | |
| Keflex 500mg PO Q6 x7d
| |
| | |
| |-
| |
| | [[Pneumonia]]<br>
| |
| |
| |
| Outpatient:
| |
| | |
| Azithromycin 500mg PO, 250mg PO x3d
| |
| | |
| ''OR''
| |
| | |
| Doxycycline 100mg PO Q12 x7d
| |
| | |
| Inpatient, Community Acquired
| |
| | |
| Ceftriaxone 1g IV
| |
| | |
| ''PLUS''
| |
| | |
| Azithromycin 500mg IV
| |
| | |
| Inpatient, Health Care Acquired
| |
| | |
| Vancomycin 1g IV ''(MRSA)''
| |
| | |
| ''PLUS''
| |
| | |
| Cefepime 2g IV ''(Pseudomonas)''
| |
| | |
| ''PLUS''
| |
| | |
| Tobramycin 4mg/kg IV ''(Pseudomonas)''
| |
| | |
| |-
| |
| | Cellulitis/Superficial Abscess
| |
| |
| |
| Bactrim DS 2tab PO Q12 x5-10d
| |
| | |
| ''PLUS''
| |
| | |
| Cephalexin 500mg PO Q6 x5-10
| |
| | |
| ''OR''
| |
| | |
| Clindamycin 450mg PO Q8 x5-10d
| |
| | |
| Diabetic with systemic toxicity
| |
| | |
| Vancomycin 1g IV
| |
| | |
| ''PLUS''
| |
| | |
| Unasyn 3g IV
| |
| | |
| ''OR''
| |
| | |
| Zosyn 3.375g IV
| |
| | |
| |-
| |
| | [[Neutropenic Fever]]<br>
| |
| |
| |
| Zosyn 4.5g IV
| |
| | |
| ''OR''
| |
| | |
| Meropenem 1g IV
| |
| | |
| ''PLUS/MINUS''
| |
| | |
| Gentamicin 2mg/kg IV
| |
| | |
| ''ADD''
| |
| | |
| Vancomycin 1g IV ''for catheter related infection, colonization with MRSA, gram-positive culture unknown susceptibility, suspected sepsis''
| |
| | |
| |}
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| <br>
| |
| | |
| == See Also ==
| |
|
| |
|
| | ==See Also== |
| *[[Antibiotics (Main)]] | | *[[Antibiotics (Main)]] |
| *[[Sepsis (Initial Abx)]] | | *[[Antibiotics by organism]] |
| | |
| == Source ==
| |
| *CURRENT Medical Dx & Tx
| |
| *University of Cincinnati Department of Emergency Medicine "Handbook of EM Fundamentals"
| |
|
| |
|
| [[Category:ID]] [[Category:Drugs]] | | ==References== |
| | <references/> |
| | [[Category:ID]] [[Category:Pharmacology]] |